Psyence Biomedical Ltd. Common Shares (PBM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Psyence Biomedical Ltd. Common Shares (PBM) has a cash flow conversion efficiency ratio of 0.060x as of December 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-662.00) by net assets ($-10.97K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Psyence Biomedical Ltd. Common Shares for the company's overall valuation and market capitalisation.
Psyence Biomedical Ltd. Common Shares - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Psyence Biomedical Ltd. Common Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Psyence Biomedical Ltd. Common Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Psyence Biomedical Ltd. Common Shares ranked by their cash flow conversion efficiency. Explore PBM cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
60 Degrees Pharmaceuticals, Inc. Common Stock
NASDAQ:SXTP
|
-0.883x |
|
Martela Oyj A
HE:MARAS
|
0.082x |
|
URU METALS LTD
F:NVRA
|
N/A |
|
QEM Ltd
AU:QEM
|
-0.341x |
|
Mid Wynd International Investment Trust plc
LSE:MWY
|
0.002x |
|
Birddog Technology Ltd
AU:BDT
|
-0.302x |
|
Haffner Energy SA
PA:ALHAF
|
-0.330x |
|
Albion Technology & General VCT PLC
LSE:AATG
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Psyence Biomedical Ltd. Common Shares (2022–2025)
The table below shows the annual cash flow conversion efficiency of Psyence Biomedical Ltd. Common Shares from 2022 to 2025. View Psyence Biomedical Ltd. Common Shares (PBM) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $6.72 Million | $-3.73 Million | -0.556x | -306.95% |
| 2024-03-31 | $-10.97 Million | $-2.95 Million | 0.268x | +12739.31% |
| 2023-03-31 | $244.66 Million | $-519.60K | -0.002x | +63.52% |
| 2022-03-31 | $239.84 Million | $-1.40 Million | -0.006x | -- |
About Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for … Read more